Ignite Creation Date:
2024-05-06 @ 5:54 PM
Last Modification Date:
2024-10-26 @ 2:38 PM
Study NCT ID:
NCT05477446
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-07-28
First Post:
2022-07-18
Brief Title:
Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With RR Langerhans Cell Histiocytosis
Sponsor:
Beijing Friendship Hospital
Organization:
Beijing Friendship Hospital
Study Overview
Official Title:
Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With Relapsed and Refractory RR Langerhans Cell Histiocytosis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-arm study to evaluate the efficacy and safety of CD207 targeted CAR-T cell therapy in relapsed and refractory langerhans cell histiocytosis
Detailed Description:
There are limited options for treatment of rr langerhans cell histiocytosis CD207 is expressed on the membrane surface of langerhans cellsand it is an ideal target for CAR-T In this study investigators will evaluate the safety and efficacy of CD207 targeted CAR- T cell therapy in patients with rr langerhans cell histiocytosis The primary goal is safety and efficiency assessment including incidence and severity of adverse events and overall response rate
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None